At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ASND Ascendis Pharma A/S
Trading 05-20 09:38:25 EDT
122.00
+0.88
+0.73%
High122.00Low121.02Vol4.48K
Open121.02D1 Closing121.12Amplitude0.81%
Mkt Cap7.00BTradable Cap6.94BTotal Shares57.35M
T/O543.91KT/O Rate0.01%Tradable Shares56.89M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Ascendis Pharma Expands Capital with Warrants and Shares
TIPRANKS  ·  05-17
Ascendis Pharma Expands Capital with Warrants and Shares
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
Benzinga  ·  05-16
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
Zacks  ·  05-15
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
Ascendis Pharma (ASND) Gets a Hold from Oppenheimer
TIPRANKS  ·  05-15
Ascendis Pharma (ASND) Gets a Hold from Oppenheimer
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Sanara MedTech (SMTI)
TIPRANKS  ·  05-15
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Sanara MedTech (SMTI)
Ascendis Pharma (ASND) Receives a Hold from TD Cowen
TIPRANKS  ·  05-15
Ascendis Pharma (ASND) Receives a Hold from TD Cowen
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Annexon Biosciences (ANNX) and Ascendis Pharma (ASND)
TIPRANKS  ·  05-15
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Annexon Biosciences (ANNX) and Ascendis Pharma (ASND)
US Equity Markets Close Higher Tuesday as Producer Prices Rise
MT Newswires  ·  05-15
US Equity Markets Close Higher Tuesday as Producer Prices Rise
FDA Delays Ascendis Pharma’s Drug Review
TIPRANKS  ·  05-15
FDA Delays Ascendis Pharma’s Drug Review
Ascendis Pharma says FDA has delayed TransCon PTH review
seekingalpha  ·  05-15
Ascendis Pharma says FDA has delayed TransCon PTH review
Ascendis Pharma Says FDA Extending Review Period for NDA
Dow Jones  ·  05-15
Ascendis Pharma Says FDA Extending Review Period for NDA
FDA extends review of Ascendis Pharma's hormone disorder therapy
Reuters  ·  05-15
FDA extends review of Ascendis Pharma's hormone disorder therapy
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (ASND), Owens & Minor (OMI) and Illumina (ILMN)
TIPRANKS  ·  05-08
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (ASND), Owens & Minor (OMI) and Illumina (ILMN)
Ascendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St.  ·  05-04
Ascendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Ascendis Pharma A/S Boasts Strong Q1 Growth
TIPRANKS  ·  05-03
Ascendis Pharma A/S Boasts Strong Q1 Growth
Ascendis Pharma Posts Q1 Revenue Growth Amid Losses
TIPRANKS  ·  05-03
Ascendis Pharma Posts Q1 Revenue Growth Amid Losses
Ascendis Pharma Outlines AGM Agenda and Proposals
TIPRANKS  ·  05-03
Ascendis Pharma Outlines AGM Agenda and Proposals

Introduction

Company Name.
Ascendis Pharma A/S
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Issue price:
--